AnaptysBio (ANAB) shares were up Monday morning after the company said its board approved a stock repurchase plan of up to $75 million, expiring Dec. 31.
The company said that as of Dec. 31, it had cash, cash equivalents and investments of more than $420 million, which are expected to fund its research and development plan through 2027.
The clinical-stage pharmaceutical company said it expects a $75 million commercial sales milestone payment from GSK (GSK) in 2025 or 2026.
Price: 19.94, Change: +2.86, Percent Change: +16.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.